Cervical neoplasia risk in IBD: Truth or hysteria?

Inflammatory Bowel Diseases

Volumn 15, Issue 11, 2009, Pages 1619-1620

  Uma, Mahadevan ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; ORAL CONTRACEPTIVE AGENT; WART VIRUS VACCINE;

CANCER RISK; CONDYLOMA ACUMINATUM; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG USE; EDITORIAL; ENTERITIS; HIGH RISK PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INNATE IMMUNITY; NONHUMAN; PAPANICOLAOU TEST; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SEXUAL BEHAVIOR; UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY; VIRUS STRAIN; WART VIRUS;

FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; RISK FACTORS; UTERINE CERVICAL NEOPLASMS;

EID: 72549094019     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20957     Document Type: Editorial

References (14)

1. Lees CW, Critchley J, Chee N, et al. Lack of association between cervical dysplasia and IBD: a large case-control study. Inflamm Bowel Dis. 2009;XX:XX-XX.
2. Bhatia J, Bratcher J, Korelitz B, et al. Abnormalities of uterine cervix in women with inflammatory bowel disease. World J Gastroenterol. 2006;12:6167-6171. (Pubitemid 44688166)
3. Hutfless S, Fireman B, Kane S, et al. Screening differences and risk of cervical cancer in inflammatory bowel disease. Aliment Pharmacol Ther. 2008;28:598-605.
4. Kane S, Khatibi B, Reddy D. Higher incidence of abnormal Pap smears in women with inflammatory bowel disease. Am J Gastroenterol. 2008;103:631-636.
5. Singh H, Demers AA, Nugent Z, et al. Risk of cervical abnormalities in women with inflammatory bowel disease: a population-based nested case-control study. Gastroenterology. 2009;136:451-458.
6. Venkatesan T BD, Ferrer V, Weber L, et al. Abnormal Pap smear, cervical dysplasia and immunomodulator therapy in women with inflammatory bowel disease. Gastroenterology. 2006;130:A-3 (abstract).
7. Connell WR, Kamm MA, Dickson M, et al. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet. 1994;343:1249-1252.
8. Kane S, Khatibi B, Reddy D. Use of immunosuppressants results in higher incidence of abnormal Pap smears in women with inflammatory bowel disease. Gastroenterology. 2006;130:A-2 (abstract).
9. Widdice LE, Moscicki AB. Updated guidelines for Papanicolaou tests, colposcopy, and human papillomavirus testing in adolescents. J Adolesc Health. 2008;43:S41-51.
10. Busnach G, Piselli P, Arbustini E, et al. Immunosuppression and cancer: a comparison of risks in recipients of organ transplants and in HIV-positive individuals. Transplant Proc. 2006;38:3533-3535.
11. Long MD, Porter CQ, Sandler RS, et al. Suboptimal rates of cervical testing among women with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2008 (in press).
12. Timmer A, Kemptner D, Bauer A, et al. Determinants of female sexual function in inflammatory bowel disease: a survey based cross-sectional analysis. BMC Gastroenterol. 2008;8:45.
13. Savoye G, Lerebours E. Abnormal Pap smears in women with Crohn's disease: is there a role for defensin deficiency? Am J Gastroenterol. 2008;103:1046-1047; author reply 1047.
14. ACOG Practice Bulletin: clinical management guidelines for obstetrician-gynecologists. Number 45, August 2003. Cervical cytology screening (replaces committee opinion 152, March 1995). Obstet Gynecol. 2003;102:417-427.